235 related articles for article (PubMed ID: 2274916)
1. 1-Desamino-8-D-arginine vasopressin (DDAVP) infusion in type IIB von Willebrand's disease: shortening of bleeding time and induction of a variable pseudothrombocytopenia.
Casonato A; Sartori MT; de Marco L; Girolami A
Thromb Haemost; 1990 Aug; 64(1):117-20. PubMed ID: 2274916
[TBL] [Abstract][Full Text] [Related]
2. Platelet aggregation and pseudothrombocytopenia induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in type IIB von Willebrand's disease patient.
Casonato A; Fabris F; Girolami A
Eur J Haematol; 1990 Jul; 45(1):36-42. PubMed ID: 2116314
[TBL] [Abstract][Full Text] [Related]
3. 1-Desamino-8-arginine-vasopressin corrects the hemostatic defects in type 2B von Willebrand's disease.
McKeown LP; Connaghan G; Wilson O; Hansmann K; Merryman P; Gralnick HR
Am J Hematol; 1996 Feb; 51(2):158-63. PubMed ID: 8579058
[TBL] [Abstract][Full Text] [Related]
4. Platelet aggregation induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in Type IIB von Willebrand's disease.
Holmberg L; Nilsson IM; Borge L; Gunnarsson M; Sjörin E
N Engl J Med; 1983 Oct; 309(14):816-21. PubMed ID: 6412139
[TBL] [Abstract][Full Text] [Related]
5. Post-DDAVP thrombocytopenia in type 2B von Willebrand disease is not associated with platelet consumption: failure to demonstrate glycocalicin increase or platelet activation.
Casonato A; Steffan A; Pontara E; Zucchetto A; Rossi C; De Marco L; Girolami A
Thromb Haemost; 1999 Feb; 81(2):224-8. PubMed ID: 10063996
[TBL] [Abstract][Full Text] [Related]
6. Re-evaluation of the therapeutic efficacy of DDAVP in type IIB von Willebrand's disease.
Casonato A; Pontara E; Dannhaeuser D; Bertomoro A; Sartori MT; Zerbinati P; Girolami A
Blood Coagul Fibrinolysis; 1994 Dec; 5(6):959-64. PubMed ID: 7893933
[TBL] [Abstract][Full Text] [Related]
7. IIB von Willebrand's disease: pathogenetic and therapeutic studies.
Kyrle PA; Niessner H; Dent J; Panzer S; Brenner B; Zimmerman TS; Lechner K
Br J Haematol; 1988 May; 69(1):55-9. PubMed ID: 3132965
[TBL] [Abstract][Full Text] [Related]
8. 1-Deamino-8-D-arginine-vasopressin--an alternative in the management of mild haemophilia A and von Willebrand's disease.
Niessner H; Korninger C
Wien Klin Wochenschr; 1983 Nov; 95(21):753-7. PubMed ID: 6424339
[TBL] [Abstract][Full Text] [Related]
9. [Thrombocytic alpha-delta-storage-pool-disease: shortening of bleeding time after infusion of 1-desamino-8-D-arginine vasopressin].
Kosch A; Kehrel B; Nowak-Göttl U; Häberle J; Jürgens H
Klin Padiatr; 1999; 211(4):198-200. PubMed ID: 10472549
[TBL] [Abstract][Full Text] [Related]
10. Combined haemophilia A and type I von Willebrand's disease: a family study including an evaluation of the effects of DDAVP infusion.
Casonato A; Pontara E; Boscaro M; Dannhauser D; Sartori MT; Girolami A
Haematologia (Budap); 1993; 25(1):57-67. PubMed ID: 8339998
[TBL] [Abstract][Full Text] [Related]
11. Von Willebrand's disease with spontaneous platelet aggregation induced by an abnormal plasma von Willebrand factor.
Grainick HR; Williams SB; McKeown LP; Rick ME; Maisonneuve P; Jenneau C; Sultan Y
J Clin Invest; 1985 Oct; 76(4):1522-9. PubMed ID: 2932469
[TBL] [Abstract][Full Text] [Related]
12. Role of platelet membrane glycoproteins Ib/IX and IIb/IIIa, and of platelet alpha-granule proteins in platelet aggregation induced by human osteosarcoma cells.
Clezardin P; Drouin J; Morel-Kopp MC; Hanss M; Kehrel B; Serre CM; Kaplan C; Delmas PD
Cancer Res; 1993 Oct; 53(19):4695-700. PubMed ID: 7691402
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of desmopressin effects on haemostasis in children with congenital bleeding disorders.
Hanebutt FL; Rolf N; Loesel A; Kuhlisch E; Siegert G; Knoefler R
Haemophilia; 2008 May; 14(3):524-30. PubMed ID: 18284449
[TBL] [Abstract][Full Text] [Related]
14. [Desamino-8-D-arginine vasopressin nose drops in the treatment of mild hemophilia A and von Willebrand's disease].
Streit A; Furlan M; Beck EA
Schweiz Med Wochenschr; 1984 Oct; 114(40):1389-91. PubMed ID: 6333722
[TBL] [Abstract][Full Text] [Related]
15. Patients with prolonged bleeding time of undefined etiology, and their response to desmopressin.
Kim HC; Salva K; Fallot PL; Karp GI; Eisele J; Matts L; Heller I; Saidi P
Thromb Haemost; 1988 Apr; 59(2):221-4. PubMed ID: 3388295
[TBL] [Abstract][Full Text] [Related]
16. Studies on the prolonged bleeding time in von Willebrand's disease.
Mannucci PM; Pareti FI; Holmberg L; Nilsson IM; Ruggeri ZM
J Lab Clin Med; 1976 Oct; 88(4):662-71. PubMed ID: 787458
[TBL] [Abstract][Full Text] [Related]
17. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
[TBL] [Abstract][Full Text] [Related]
18. The use of desmopressin in von Willebrand disease: the experience of the first 30 years (1977-2007).
Federici AB
Haemophilia; 2008 Jan; 14 Suppl 1():5-14. PubMed ID: 18173689
[TBL] [Abstract][Full Text] [Related]
19. Laboratory diagnosis and monitoring of desmopressin treatment of von Willebrand's disease by flow cytometry.
Giannini S; Mezzasoma AM; Leone M; Gresele P
Haematologica; 2007 Dec; 92(12):1647-54. PubMed ID: 18055988
[TBL] [Abstract][Full Text] [Related]
20. Clinical experience with arginine vasopressin (DDAVP) in von Willebrand's disease and mild haemophilia.
Ockelford PA; Menon NC; Berry EW
N Z Med J; 1980 Nov; 92(672):375-8. PubMed ID: 6970907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
